Introduction
T he annual winter outbreak of influenza is one of the major causes of morbidity and mortality among frail elderly people 1, 2 who are at increased risk for serious complications, including hospitalization and death. [3] [4] [5] Additionally, influenza results in high health care costs and represents a relevant clinical and economic burden on the patient and society. 6, 7 Similarly, the burden of invasive pneumococcal disease (IPD) is high, with the highest incidence and case fatality rate in the older population. 8 The overall incidence of IPD in Europe in 2010 was 5.2 cases per 100 000 population, with 15.6 cases per 100 000 in !65 years old. 9 Mortality rates due to IPD have remained high despite the availability of clear guidelines for treatment and a number of highly effective antibiotics. 10 Influenza and pneumococcal vaccinations have been proved safe and effective in preventing and controlling infection [11] [12] [13] [14] and have been recommended in many countries. [15] [16] [17] However, systematic literature reviews have produced conflicting results about their efficacy in the elderly population. [18] [19] [20] [21] Aims of this study were to assess the prevalence of influenza and pneumococcal vaccination and to evaluate their association with allcause mortality in a large European population of frail and old people living in nursing homes (NHs).
Methods

SHELTER study: study design, setting and participants
The study population consisted of 4156 NH residents in 57 facilities of 7 European Union (EU) countries (Czech Republic, England, Finland, France, Germany, Italy and The Netherlands) and 1 non-EU country (Israel), participating to the Services and Health for Elderly in Long-TERm care (SHELTER) study. 22 SHELTER is a prospective cohort study aimed at validating the 'international resident assessement instrument for long-term care facilities (interRAI-LTCF), and at implementing this instrument on a larger scale, leading to the creation of a database collecting information on NH residents in Europe. In each country, study partners identified a sample of NH willing to participate in the study. This sample must not be considered randomly selected and is not intended to be representative of all NHs in each country. Older adults residing in participating NH at the beginning of the study and those admitted within the 3-month enrollment period after the initiation of the study were assessed by the interRAI-LTCF. No exclusion criterion was adopted.
Ethics approval
Ethical approval for the study was obtained in all countries according to local regulations. Residents were invited to take part in the study and were free to decline participation. Written informed consent was obtained with assurance of data confidentiality.
Data sources: interRAI-LTCF
The interRAI-LTCF contains over 350 data elements including socio-demographic variables, numerous clinical items about both physical and cognitive status and all clinical diagnoses. 23, 24 The interRAI-LTCF also includes information about an extensive array of signs, symptoms, syndromes and treatments being provided. As shown by the main results of the SHELTER study, the interRAI-LTCF is a reliable instrument to assess and compare characteristics of NH residents across countries, languages and cultures. 25 Study researchers responsible for data collection were trained following a previously validated procedure to use a variety of information sources, such as direct observation, interviews with the person under care, family, friends or formal service providers and review clinical records, both medical and nursing. 26 
Study variables
Influenza and pneumococcal vaccination
According to interRAI-LTCF manual, we used a single question to assess administration of influenza vaccine in the last year. The use of this variable regarding the vaccination has already been proved a validated instrument for health research in this specific field. 25 Similarly, a single question was used to assess administration of pneumococcal vaccination at any time after the age of 65 years. For a statistical purpose, we created a combined variable of influenza and pneumococcal vaccination with four categories ('neither influenza nor pneumococcal vaccination'; 'influenza vaccination'; 'pneumococcal vaccination' and 'both vaccinations').
Covariates
The demographic variables included age and gender. The cognitive performance scale (CPS) was used to assess cognitive status. The CPS combines information on memory impairment, level of consciousness and executive function, with scores ranging from 0 (intact) to 6 (very severe impairment). 27 To evaluate functional status, the seven-point multi domains scale (MDS) activities of daily living hierarchy scale (ADLh) was used. 28 The ADLh groups activities of daily living according to the stage of the disablement process in which they occur. The ADLh ranges from 0 (no impairment) to 6 (total dependence). The MDS depression rating scale (DRS) was used to assess the presence of depressive symptoms and a score ! 3 was used to diagnose depression. 29 Clinical diagnoses were recorded by a physician, gathering information from the patient and his/her general practitioner and from physical examination, careful review of patient clinical documentation and previous medical history. Data about drugs residents received in the 3 days prior to the assessment were collected gathering information from physician order sheets and drug administration records.
Mortality
Residents were followed during their stay in NH and all deaths were recorded. Time to death was calculated from the date of the first assessment to the date of death. The survival times of the participants that did not die during follow-up were censored at discharge from NH or at the end of follow-up time (maximum 12 months).
Statistical methods
From the initial sample of 3966 over 65 years residents (190 patients were younger than 65 years old and were thus not included in this study), we excluded those with missing information regarding vaccination status (n = 66, 1.7%) and those with missing follow-up data (n = 390, 10%), resulting in a final sample of 3510 participants.
Differences in socio-demographic status, functional, cognitive and clinical characteristics between vaccinated and not-vaccinated patients are given in table 1. The mortality and crude incidence rate for death according to vaccination status have been computed. To assess the impact of influenza and pneumococcal vaccinations on mortality, the combined variable of influenza and pneumococcal vaccination was entered in a Cox regression model as independent variable. The assumption of proportionality of the hazards was graphically tested. No departure from the proportional hazards assumption was detected. Furthermore, the crude model was adjusted for potential confounders, including age and sex, as well as for the socio-demographic status, functional, cognitive and clinical characteristics. 25 This adjusted model adopted the sharedfrailty Cox function with the country information as grouping variable to take into account the potential dependencies in vaccination administration due to national immunization policies. Possible interactions between the main covariates have been investigated and kept in if statistically significant or clinically relevant.
A P < 0.05 value was chosen for statistical significance. All analyses were performed using IC STATA14 software for Mac.
Results
The mean age of the 3510 participants was 84.6 years (SD = 7.7 years) and 2624 (74.8%) were female. More than one-half of the population (51.2%) was aged 85 years or older, with 9.0% of over 95. Overall, patients had a moderate-to-severe functional and cognitive impairment (mean ADLh = 3.4; SD = 1.9; mean CPS = 2.9; SD = 2.1). The mean number of disease was 2.4 (SD = 1.5) and the mean number of drug was 7.0 (SD = 3.6).
Overall, 2866 residents (81.7% of the study sample) received influenza vaccination. Wide geographical variations were evident: Italy and France collected the highest rates with 92.8% of the population vaccinated, followed by Finland and Israel with 92.0%. The lowest rate was found in the Czech Republic (57.0%). The pneumococcal vaccination rates were globally lower: 948 (27.0%) resident received pneumococcal vaccination with a great variability among different countries: the highest rate was observed in Israel (70.1%), the lowest in Finland (1.4%) and The Netherlands (1.0%). Table 1 represents the main characteristics of the study population according to influenza and pneumococcal vaccination. In both cases, the vaccinated groups were older. People who received pneumococcal vaccine were more dependent in the activity of daily living (3.7 vs. 3.4 in ADLh), while no relevant differences were present between the influenza vaccinated and not-vaccinated groups. In both vaccinated groups, there was a higher level of cognitive impairment (CPS 2.9 vs. 2.5 in influenza and 3.1 vs. 2.7 in pneumococcal vaccination). Also, residents receiving vaccinations presented more comorbidity, with a higher number of diseases in both influenza (2.4 vs. 2.3) and pneumococcal (2.6 vs. 2.3) vaccinated people. Finally, those who received the influenza vaccination presented a higher rate of depression, as assessed by a DRS score ! 3 (32.7 vs. 28.3%). No differences in the number of drugs were highlighted in the two groups. Figure 1 shows the distribution of the different vaccinations in the study population. Among those who received pneumococcal vaccination (27%), the majority (25.5%) also received influenza vaccination. Only 53 subjects (1.5% of the study population), received only anti-pneumococcal vaccine, showing that most of the patients who received pneumococcal are highly likely to also receive influenza vaccination.
Overall, 727 patients (20.7%) died during the 1-year follow-up. As shown in table 2, mortality rate was higher in the not vaccinated than in the vaccinated groups. Overall, a 38% reduction of the crude hazard ratio for mortality was observed in the influenza vaccinated group as compared with the not-vaccinated group (P < 0.001). A 46% reduction of the crude hazard ratio for mortality was observed in pneumococcal vaccinated group as compared with the not-vaccinated group (P = 0.09). Furthermore, the combination of influenza and pneumococcal vaccination reduce the mortality rate of 38% as compared with the not-vaccinated group (P < 0.001).
Shared-frailty Cox regression model adjusted for age, sex, number of diseases, CPS, ADLh and depression (DRS ! 3) showed that influenza vaccinated residents had a lower mortality rate compared with not-vaccinated residents (HR, 0.80; 95% CI 0.66-0.97) (table 3). Furthermore, residents receiving pneumococcal vaccination had a lower but not significant mortality rate compared with not-vaccinated residents (HR, 0.52; 95% CI 0.25-1.06). Finally, residents receiving the combination of influenza and pneumococcal vaccination had a significant lower mortality rate compared with not-vaccinated residents (HR, 0.72; 95% CI 0.57-0.91) (table 3).
Discussion
In this observational prospective cohort study, we found that influenza vaccination rate was higher than 80% in NH residents but <30% of the study sample received pneumococcal vaccination. Influenza vaccination had a protective effect in terms of survival, regardless of age, sex, comorbidity and other functional status confounders. Also the combination of the two vaccinations has shown a significant reduction in the mortality in respect of the absence of vaccination.
Seasonal influenza-related mortality is very high, especially in geriatric population. The estimate of vaccine-prevented deaths varies every year depending on the vaccine efficacy, the intensity of the influenza epidemic, the virulence of the circulating virus and the pre-existing immunity level of the population.
Many authors demonstrated that inactivated influenza vaccine can prevent much of the illness and deaths caused by influenza. 12, 13, 25, [30] [31] [32] Nichol et al. 33 demonstrated, in a large population study that in a time span of 10 years influenza vaccination was associated with a 48% reduction of the mortality. Although in 2010, a Cochrane review concluded that the available evidence was of poor quality and provided no guidance regarding the effectiveness of vaccines in preventing influenza, influenza-like illness, hospital admission, complications and mortality for people aged 65 years or older, 19 more recent data showed that from August 2005 to June 2014, influenza vaccination has prevented 40 127 deaths in USA, most of them (88.9%) in seniors over 65 years. 34 Another recent study involving 1958 elderly residents in 58 NHs in Hong Kong showed a 28% reduction in all-cause and pneumoniarelated mortality during 1-year follow-up in patients undergoing trivalent influenza vaccination, 35 a value comparable to that obtained in our analysis.
Pneumococcal infection also represents an important cause of morbidity and mortality in elderly population but vaccination efficacy has been questioned in the last years. 21, 36 However, a recent study evaluating a national vaccination program with the 23-valent pneumococcal polysaccharide vaccine carried out in Taiwan over 75 years population, showed over 90% reduction in mortality from all causes in the vaccinated group. 37 In recent years, the community-acquired pneumonia immunization trial in adults found statistically significant efficacy of the 13-valent pneumococcal conjugated vaccine in preventing 46% of vaccine-type community-acquired pneumonia, and of 75% IPD along with an acceptable safety profile. 38 Our study presents some potential limitations. First of all, like other observational studies, even if the statistical analysis was adjusted for numerous covariates, significant differences between the two groups may have been left, biasing the study results. However, the use of the interRAI-LTCF, a multidimensional assessment instrument, allows a comprehensive investigation of the different domains of elderly health status, providing a complete, exhaustive and standardized assessment.
In addition, since our study regarded institutionalized older adult, we are not authorized to extend these results to the general geriatric population. Indeed, it is likely that in this particular care setting medical personnel pays particular attention to preventive strategies such as vaccinations.
A third point is the lack of information about the specific type of influenza and pneumococcal vaccine received by each patient. Anyway, it could be assumed that residents had been vaccinated according to their clinical conditions (i.e. age and comorbidities) and the available vaccines in each country and facility. ADLh, ADL hierarchy; CPS, cognitive performance scale. 39 For the pneumococcal disease, it could be supposed that most of patients received the 23 serotypes polysaccharides vaccine. Unfortunately neither information regarding previous immunization status for influenza nor the time since the influenza or pneumococcal vaccinations were included in the interRAI-LTCF manual and they were not recorded. However, this approach is consistent with previously published studies carried out on similar population in different setting. 25, 40 Lastly, 10% of the originally included persons had no follow-up information but they did not showed any significant difference in the other variables of interest in respect of the patients included in the survival analysis. Consequently, this limitation should not have influenced the model and the interpretation of the results.
Strength of our study is undoubtedly the multicentre characteristic of the study population and the high number of patients enrolled. Considering the difficulty to involve elderly subjects in randomized clinical trials, well-designed outcomes-oriented research can be used to supplement clinical trials information and to determine the effectiveness of specific treatments or preventive measures, such as vaccination. 41 
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Key points
This observational prospective cohort study highlights how influenza vaccination have a protective effect reducing the instantaneous death rates of 20% in older adult living in nursing homes, regardless of age, sex, comorbidity and other possible confounders. Better significant results have been found for the combination of influenza and pneumococcal vaccination in respect of the absence of vaccination but not for pneumococcal vaccination alone. Our findings highlight the urgency to improve effective vaccine utilization programmes among frail elderly people, with a special attention to pneumococcal vaccination. All health care providers should take advantage of every opportunity to vaccinate this high-risk subjects group. 
